Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00709098 · ClinicalTrials.gov registry record · Phase 3
Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension
A Phase 3 study, sponsored by Actelion.
- Completed
- Registry status
- Phase 3
- Development phase
- 49
- Enrollment target
NCT00709098 is a Phase 3 study that has completed, run by Actelion. The registered enrollment target is 49 participants.
The verdict
NCT00709098, a Phase 3 study, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 49 participants
- Enrollment target
Study Summary
Patients with symptomatic idiopathic (IPAH) or familial (FPAH) pulmonary arterial hypertension in New York Heart Association (NYHA) class II to IV , naive to PAH treatment or currently being treated with a stable dose of either bosentan or sildenafil and who complete PROWESS 15 will be enrolled in the PROWESS 15 Extension study. This is a double-blind (12 week), randomized study to compare the safety and tolerability of inhaled iloprost power disc-15 and power disc-6 in patients with symptomatic pulmonary arterial hypertension (PAH). After completion of the double blind period, patients will be entered in the open label period using iloprost power disc-15.
Interventions
- DRUG iloprost
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00709098
The ClinicalTrials.gov registry entry for NCT00709098 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which iloprost is the first listed.
NCT00709098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00709098 about?
NCT00709098 is a clinical study titled "Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension". Patients with symptomatic idiopathic (IPAH) or familial (FPAH) pulmonary arterial hypertension in New York Heart Association (NYHA) class II to IV , naive to PAH treatment or currently being treated with a stable dose of either bosentan or sildenafil and who complete PROWESS 15 will be enrolled in t...
What is the current status of trial NCT00709098?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 49 participants. The study started on 2008-09. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00709098?
The interventions under investigation include: iloprost (DRUG).
Who is sponsoring clinical trial NCT00709098?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.